Anti-HIV drugs may damage unborn babies' hearts

Image
Press Trust of India Washington
Last Updated : Nov 23 2014 | 1:30 PM IST
Drugs often given to HIV-positive pregnant women may cause significant long-term heart problems for the non-HIV-infected babies they carry, a new study suggests.
The study shows that while the HIV medications have been successful in helping to prevent the transmission of the virus from mother to infant, they are associated with persistently impaired development of heart muscle and reduced heart performance in non-HIV-infected children whose mothers received the medicines years earlier.
"What our study indicates is that there's potentially a long-term price to be paid for protecting the children of HIV-infected mothers from the virus," said Steven Lipshultz, pediatrician-in-chief at the Children's Hospital of Michigan and chair of pediatrics for the Wayne State University School of Medicine.
"These medicines have been very effective at reducing the rate of transmission of HIV from mother to child, but the findings we've just published show clearly that further investigation of their long-term impact on the heart health of the children involved is needed," said Lipshultz, the lead author of the study.
"Thanks to the new anti-HIV medications, the rate of transmission has been lowered from 26 per cent to less than 1 per cent during the past few decades, and that has been a miracle of life for the children involved. Still, we don't want to be protecting these children from one disease, only to give them another one," said Lipshultz.
The study compared heart development and long-term heart functioning in 428 uninfected children of HIV-infected mothers to children who had not been exposed to HIV from 2007 to 2012.
The results pointed to a significant association between lagging heart muscle development and impaired pumping ability in the children of the HIV-infected mothers who had received the medications.
"Subclinical differences in left ventricular structure and function with specific in-utero antiviral exposures indicate the need for a longitudinal study to assess long-term cardiac risk and cardiac monitoring recommendations," said Lipshultz.
The study was published in the journal AIDS.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Nov 23 2014 | 1:30 PM IST

Next Story